What is insider trading data?

Insider trading data comes from SEC Form 4 filings, which corporate insiders must file within 2 business days of buying or selling company stock. This includes CEOs, CFOs, directors, and major shareholders.

How do I track congressional stock trades?

InsiderStreet.ai aggregates financial disclosures from the STOCK Act, showing stock trades by members of Congress. These are typically disclosed within 45 days of the transaction.

What are 13F filings?

13F filings are quarterly reports that institutional investment managers with over $100 million in assets must file with the SEC, revealing their equity holdings.

ATHE - Alterity Therapeutics Limited

Name: Alterity Therapeutics Limited (ATHE) Financial Data
Creator: InsiderStreet.ai
License: https://insiderstreet.ai/terms

PRNAF (OTC) is a cross-listing of ATHE (NASDAQ). Showing primary listing data.

$3.41

+0.04 (+1.34%)

After Hours: $3.65 (+0.24, +7.04%)

NASDAQ · Healthcare · Biotechnology · $30.9M · Alpha Radar Neutral · Power 55

Smart Money Score

No convergence signal

Key Statistics

Market Cap$30.9M

52W Range2.52-7

Volume3,152

Avg Volume12,538

Beta0.05

Dividend—

Analyst Ratings

4 Buy 4 Hold 0 Sell

Consensus Buy

Company Info

CEODavid A. Stamler

Employees10

SectorHealthcare

IndustryBiotechnology

IPO Date2003-09-29

Websitealteritytherapeutics.com

460 Bourke Street
Melbourne, VIC 3000
AU

61 3 9349 4906

About Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Latest News

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

GlobeNewsWire-FDA · 2w ago

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

Benzinga-Biotech · 2w ago

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

Benzinga-News · 3w ago

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Bullish Benzinga-News · 3w ago